- Home
- COLL vs KDK Comparison
COLL vs KDK Comparison
Compare COLL & KDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | KDK |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | KDK |
|---|---|---|
| Price | $45.76 | $8.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $51.17 | $15.63 |
| AVG Volume (30 Days) | 406.2K | ★ 463.4K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $757,067,000.00 | $16,450,000.00 |
| Revenue This Year | $26.17 | N/A |
| Revenue Next Year | $3.65 | $253.02 |
| P/E Ratio | $28.17 | ★ N/A |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $5.43 |
| 52 Week High | $50.79 | $11.62 |
Technical Indicators
Market Signals| Indicator | COLL | KDK |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 43.17 |
| Support Level | $43.99 | $8.28 |
| Resistance Level | $49.31 | $9.45 |
| Average True Range (ATR) | 1.62 | 0.43 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 38.19 | 22.60 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About KDK Kodiak AI Inc.
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.